Related Experiment Videos
Efficacy and long-term adverse effect pattern of lovastatin
1Department of Clinical Research, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey 07065.
The American Journal of Cardiology
|November 11, 1988
Summary
Lovastatin effectively lowers cholesterol by inhibiting HMG CoA reductase. This cholesterol-lowering drug demonstrates good tolerability and a favorable safety profile in extensive clinical use.
Area of Science:
- Cardiovascular Pharmacology
- Lipid Metabolism
- Pharmacovigilance
Background:
- Lovastatin is a well-established HMG CoA reductase inhibitor.
- Numerous studies confirm its efficacy in lipid-lowering therapy.
Purpose of the Study:
- To summarize the clinical efficacy and safety profile of lovastatin.
- To report on long-term safety data and post-marketing experience.
Main Methods:
- Analysis of data from clinical trials and a long-term safety study.
- Review of adverse event reports and patient data up to March 1988.
Main Results:
- Lovastatin (40 mg BID) reduced total cholesterol by 33% and LDL cholesterol by 41%.
- It increased HDL cholesterol by 9% and reduced the HDL/LDL ratio by 44%.
- Serious adverse effects included myopathy (0.5%) and elevated transaminases (1.9%), both reversible upon discontinuation.
Conclusions:
- Lovastatin demonstrates significant efficacy in reducing plasma cholesterol levels.
- The drug exhibits good tolerability and a favorable safety profile, supported by extensive clinical trial data and real-world usage.
- Adverse effects are generally reversible, with myopathy primarily observed in specific patient subgroups.